Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3729020 | 0.87 | SMN1; SMN2 (0.38) | L3MBTL1SMYD3EPHX1KMT2ASIGMAR1 | |
| SCHEMBL3719801 | 0.87 | SMN1; SMN2 (0.38) | L3MBTL1SMYD3EPHX1KMT2ASIGMAR1 | |
| SCHEMBL19975443 | 0.80 | MEN1 (0.55) | KMT2ALMNAMEN1 | |
| SCHEMBL4098800 | 0.80 | CPB2 (0.41) | EPHX1KMT2AHPGD | |
| Hydrochloric Acid SCHEMBL16007751 | 0.78 | HDAC4 (0.46) | EPHX1KMT2A | |
| SCHEMBL21526199 | 0.76 | TDP1 (0.48) | L3MBTL1KDM4EHPGD | |
| SCHEMBL1989246 | 0.76 | TDP1 (0.48) | L3MBTL1KDM4EHPGD | |
| SCHEMBL3274629 | 0.75 | GPR88 (0.37) | L3MBTL1SMYD3EPHX1KMT2ASIGMAR1 | |
| SCHEMBL842056 | 0.74 | SMYD3 (0.45) | L3MBTL1SMYD3EPHX1KMT2ASIGMAR1 | |
| SCHEMBL2362012 | 0.74 | SMYD3 (0.45) | L3MBTL1SMYD3EPHX1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2782903-B1 | NOVEL PYRROLIDINE DERIVATIVES AS INHIBITORS OF CATHEPSIN | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | disclosed |
| US-8729061-B2 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130137687-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137687-A1 | NOVEL PYRROLIDINE DERIVATIVES | PYCR1, PRMT7, PRLHR | L3MBTL1 4342/4885SMYD3 3271/4885EPHX1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.